Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PF-06650833, PF-06700841, and PF-06826647 in adults with hidradenitis suppurativa (acne inversa) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• PF-06650833 (PF-06650833)
• PF-06700841
• PF-06826647

Snippet

Sponsor: Pfizer | Conditions: Acne Inversa | Phase 2 | Status: COMPLETED | Results posted: 2023-06-15